Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic ...

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...

How weight loss drugs may trigger severe muscle loss

Explore how popular weight loss medications like Wegovy and Mounjaro can lead to substantial muscle loss, especially in older ...
Kentucky Lantern

Kentucky Republican wants to remove BMI from eating disorder treatment standards. Here’s why.

Louisville Rep. Ken Fleming will file a bill to remove body mass index from treatment standards for state qualified health ...

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the ...

How to calculate your BMI to see if you are underweight, overweight, or healthy? Check the health risks of low and high BMI

Body Mass Index (BMI) is a key tool for assessing weight categories and potential health risks, estimating body fat based on ...
Lupus Science & Medicine

Proteomic analysis reveals angiogenesis-related plasma proteins associated with pre-eclampsia in SLE

Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE.